180463-06-3

Upstream product

• 1149-26-4 (S)-N-(benzyloxycarbonyl)valine 
• 501-53-1 benzyl chloroformate 
• 2443-71-2 benzyl (S)-(1-hydrazineyl-3-methyl-1-oxobutan-2-yl)carbamate 
• 72-18-4 L-valine 
• 68199-62-2 <(benzyloxycarbonyl)-L-valinyl>hydrazinecarboxylic acid tert-butyl ester 

Downstream Products

• 180463-23-4 {(S)-1-[N'-((2S,3S)-3-{(S)-3-Carbamoyl-2-[(quinoline-2-carbonyl)-amino]-propionylamino}-2-hydroxy-4-phenyl-butyl)-N'-isobutyl-hydrazinocarbonyl]-2-methyl-propyl}-carbamic acid benzyl ester 
• 180463-09-6 (S)-N¹-{(1S,2S)-3-[N'-((S)-2-Amino-3-methyl-butyryl)-N-isobutyl-hydrazino]-1-benzyl-2-hydroxy-propyl}-2-[(quinoline-2-carbonyl)-amino]-succinamide 
• 180463-08-5 {(S)-1-[N'-((2S,3S)-3-Amino-2-hydroxy-4-phenyl-butyl)-N'-isobutyl-hydrazinocarbonyl]-2-methyl-propyl}-carbamic acid benzyl ester 
• 180463-07-4 {(1S,2S)-1-Benzyl-3-[N'-((S)-2-benzyloxycarbonylamino-3-methyl-butyryl)-N-isobutyl-hydrazino]-2-hydroxy-propyl}-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability

A series of aza-peptide analogs with a (hydroxyethyl)hydrazine isostere has been synthesized as HIV-1 protease inhibitors using a simple synthetic scheme. Structure-activity studies based on the X-ray of a previously described inhibitor-enzyme complex led to potent inhibitors with antiviral activity in the low-nanomolar range. The S-configuration of the transition- state hydroxyl group was preferred in this series. Small modifications of the P2P3 and P2'P3' substituents had little effect on enzyme inhibition but greatly influenced the pharmacokinetic profile. As a result of these studies, the symmetrically acylated compound 8a and its close analog 24a bearing a methyl carbamate in P3 and an ethyl carbamate in P3' position were identified as potent inhibitors with plasma concentrations exceeding antiviral ED50 values 150-fold following oral application in mice.